NALIRIFOX - A Groundbreaking 4-Drug Combo Approved By The U.S. FDA For Metastatic Pancreatic Cancer

Pancreatic Cancer News: Metastatic pancreatic adenocarcinoma, a particularly challenging form of cancer, has received a significant breakthrough with the recent approval of NALIRIFOX by the U.S. Food and Drug Administration (FDA). NALIRIFOX is a groundbreaking four-drug chemotherapy regimen consisting of irinotecan liposome (Onivyde), oxaliplatin, leucovorin, and fluorouracil. The approval follows the promising results of the NAPOLI 3 trial, led by Dr Zev Wainberg, co-director of the UCLA Health GI Oncology Program and a researcher at the UCLA Health Jonsson Comprehensive Cancer Center.


NALIRIFOX - A Groundbreaking 4-Drug Combo Approved By
The U.S. FDA For Metastatic Pancreatic Cancer

NAPOLI 3 Trial: A Milestone in Pancreatic Cancer Research
The NAPOLI 3 trial, covered in this Pancreatic Cancer News report, which included 770 patients with pancreatic ductal adenocarcinoma, stands out as a landmark study in the realm of metastatic pancreatic cancer research. Patients were randomly assigned to receive either NALIRIFOX or a two-drug therapy comprising nab-paclitaxel (Abraxane) and gemcitabine. The results, initially presented at the 2023 American Society of Clinical Oncology Gastrointestinal Cancers Symposium and published in The Lancet in October 2023, demonstrated that NALIRIFOX led to longer overall survival than the two-drug protocol.
 
Survival Benefits and Improved Progression-Free Survival
Patients in the NALIRIFOX group exhibited an overall survival of 11.1 months, compared to 9.2 months in the two-drug arm. Additionally, progression-free survival saw an increase with NALIRIFOX, extending to 7.4 months versus 5.6 months with the two-drug regimen. This translated to a notable 30% reduction in the risk of disease progression or death. Importantly, the NAPOLI 3 trial is a rarity in metastatic pancreatic cancer studies, being the first in nearly a decade to achieve a positive endpoint for overall survival.
 
The Pancreatic Cancer Challenge
Pancreatic cancer, particularly when diagnosed at advanced stages, poses a significant challenge due to its aggressiveness and limited treatment options. The disease's high fatality rate is exacerbated by the fact that only about 13% of patients survive five or more years. In 2024 alone, an estimated 35,000 people are anticipated to succumb to pancreatic cancer in the United States, according to the American Cancer Society.
 
Dr Wainberg's Perspective
Dr Zev Wainberg, the global principal investigator for the NAPOLI 3 trial, emphasized the significance of the FDA approval, especially considering the historical difficulty in treating metastatic pancreatic cancer. As a professor of medicine at the David Geffen School of Medicine at UCLA, he noted that the study represents a potential new benchmark standard for current therapies, offering a promising avenue for ongoing research and drug development.
 
NALIRIFOX Safety Profile
The safety profile of NALIRIFOX was asses sed during the trial, with participants reporting common side effects such as diarrhea, fatigue, nausea, vomiting, reduced appetite, abdominal pain, mucosal inflammation, constipation, and decreased weight. Despite these side effects, the FDA deemed the benefits of the treatment significant enough to warrant its approval, marking a critical step forward in addressing the challenges posed by metastatic pancreatic cancer.
 
NAPOLI 3 Trial Design and Methodology
The NAPOLI 3 trial, conducted at 187 community and academic sites across 18 countries, compared the efficacy and safety of NALIRIFOX with nab-paclitaxel and gemcitabine as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients with mPDAC and Eastern Cooperative Oncology Group performance status scores of 0 or 1 were randomly assigned to receive NALIRIFOX or the two-drug therapy.
 
Significant Findings and Implications
The key findings of the NAPOLI 3 trial, demonstrating a statistically significant and clinically meaningful improvement in overall survival and progression-free survival with NALIRIFOX, have important implications for the future treatment landscape of metastatic pancreatic cancer. The trial, with its large sample size and global recruitment, provides a new reference standard for first-line treatment.
 
Comparisons with Existing Regimens
Notably, NAPOLI 3 is the first study to demonstrate the superiority of quadruplet therapy, utilizing liposomal irinotecan, over doublet therapy with nab-paclitaxel and gemcitabine. Previous trials, such as the PRODIGE 4/ACCORD 11 trial, compared FOLFIRINOX with gemcitabine alone, leading to its adoption as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. However, NAPOLI 3's results contribute a unique perspective, showing the advantages of NALIRIFOX over nab-paclitaxel and gemcitabine in terms of both overall survival and progression-free survival.
 
Safety Considerations and Tolerability
One notable aspect of the NALIRIFOX regimen is its relatively favorable safety profile. Patients remained on NALIRIFOX for a median of 6 weeks longer than those receiving nab-paclitaxel and gemcitabine, indicating better tolerability. Furthermore, rates of grade 3–4 peripheral neuropathy were lower in the NALIRIFOX group than in the nab-paclitaxel and gemcitabine group.
 
Future Research Directions
Looking ahead, ongoing research will explore additional dimensions of NALIRIFOX, including cost implications and its impact on health-related quality of life. Genomic profiling evaluations from the NAPOLI 3 trial may also shed light on patient selection criteria, potentially identifying subgroups that could particularly benefit from this innovative treatment approach.
 
Conclusion
The FDA approval of NALIRIFOX for the first-line treatment of metastatic pancreatic adenocarcinoma marks a significant advancement in the field. The NAPOLI 3 trial's robust design, global reach, and positive outcomes position NALIRIFOX as a promising reference regimen, offering renewed hope for patients facing the challenges of this aggressive and difficult-to-treat cancer. As research and drug development continue, NALIRIFOX's success serves as a beacon for future innovations in the battle against metastatic pancreatic cancer.
 
The study findings were published in the peer reviewed journal: The Lancet.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01366-1/fulltext
 
For the latest Pancreatic Cancer News, keep on logging to Thailand Medical News.